Effects of certain pre-analytical factors on the performance of plasma phospho-tau217

Table 1 Participant characteristics

	Total (n = 100)	Aβ⁺ (n = 50)	Aβ⁻ (n = 50)	P-value Aβ⁻ vs Aβ⁺
Age (year)	77.5 (80–40)	77.5 (80–74.75)	77.5 (81–73.75)	0.967
Diagnosis CU/MCI/ADD/VaD/ NPH, n	83/6/8/2/1	35/6/8/1/0	48/0/0/1/1	0.002
Sex (female/male), n	63/37	33/17	30/20	0.534
Education, years	11 (13.75–9)	11 (13.25–9)	12 (14–9.75)	0.577
MMSE score	28 (29–27)	28 (29–26)	29 (29.25–28)	0.005
APOE \(\varepsilon 4\) status pos./neg. (%pos.)	38/61 (38.4%)	29/21 (58%)	9/40 (18.4%)	0.001
CSF p-tau217, pg/ml	9.44 (21.89–5.27)	21.68 (34.84–13.93)	5.73 (7.91–4.42)	< 0.001

Data are shown as median (interquartile range). Group differences were analyzed using the Mann–Whitney test. For sex and APOE \(\varepsilon 4\) status, the chi-square test was used. Abbreviations: Aβ⁺ Amyloid-β positive, Aβ⁻ Amyloid-β negative, ADD Alzheimer disease dementia, APOE Apolipoprotein E, CSF Cerebrospinal fluid, CU Cognitively unimpaired, MCI Mild cognitive impairment, MMSE Mini-Mental State Examination, NPH Normal pressure hydrocephalus, VaD Vascular dementia

ISSN: 1758-9193